Medical School · Year 2 · Reproductive · includes a quiz and discussion video

Lecture 9: Postpartum Period

Unit 2.4: Reproductive System

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the normal physiologic changes of the puerperium
2. Explain lactation physiology and breastfeeding support
3. Describe postpartum hemorrhage and its management
4. Explain postpartum infections and thromboembolic disease
5. Describe postpartum mood disorders
6. Explain postpartum contraception and family planning

Section 1: The Puerperium - Involution and Physiologic Recovery

The puerperium, defined as the six-week period following delivery, marks the transition from pregnancy to the non-pregnant state. During this time, the dramatic anatomic and physiologic changes of pregnancy reverse, the mother recovers from delivery, and lactation is established.

Uterine involution represents one of the most dramatic postpartum changes. Immediately after delivery, the uterus weighs approximately 1000 grams and is palpable at the umbilicus. By the end of the first postpartum day, the fundus descends to approximately one centimeter below the umbilicus. By one week, the uterus has descended to the level of the pubic symphysis and weighs approximately 500 grams. By six weeks, the uterus has returned to its non-pregnant size of 50-100 grams. This remarkable reduction results from multiple processes: contraction of myometrial fibers, autolysis of cellular proteins, and ischemia of compressed tissue. The contraction of interlacing myometrial fibers around blood vessels, creating the "living ligatures," is critical for hemostasis at the placental site.

Lochia, the vaginal discharge following delivery, reflects the healing of the endometrium and provides important clinical information. Lochia rubra, present during the first three to four days, consists predominantly of blood and decidual tissue and is bright red. Lochia serosa, appearing from approximately days 4-10, is pink-brown and contains blood, cervical mucus, and leukocytes. Lochia alba, beginning around day 10 and lasting up to 3-4 weeks, is white-yellow and consists primarily of leukocytes, decidual cells, and bacteria. A return to bright red bleeding after lochia alba has appeared, foul-smelling discharge, or persistent heavy bleeding should raise concern for retained products of conception, endometritis, or subinvolution.

The cervix, which dilates to 10 cm during labor, begins to contract immediately after delivery. By the end of the first week, the cervical os admits only a fingertip. The external os never returns to its nulliparous circular shape, instead assuming the characteristic transverse slit of the parous cervix. The vagina gradually recovers its tone over several weeks, though estrogen deprivation from breastfeeding may result in persistent atrophy and dryness.

<image>Panel A: Uterine descent timeline with anatomical cross-sections showing immediately postpartum (fundus at umbilicus, 1000g), day 1 (1 cm below umbilicus), day 7 (at symphysis, 500g), and 6 weeks (non-pregnant size, 50-100g). Panel B: Involution mechanism inset showing myometrial fiber contraction creating "living ligatures" around blood vessels for hemostasis at the placental site. Panel C: Lochia stages with color representation showing lochia rubra (days 1-3, bright red), lochia serosa (days 4-10, pink-brown), and lochia alba (days 11-21+, white-yellow), with warning signs for return to red bleeding, foul odor, or persistent heavy bleeding. Panel D: Cervical changes from fully dilated (10 cm) through progressive contraction to the characteristic transverse slit of the parous external os.</image>

Section 2: Systemic Physiologic Changes Postpartum

The cardiovascular adaptations of pregnancy resolve over weeks following delivery. Blood volume, which increased 40-50% during pregnancy, returns to baseline by approximately six weeks through diuresis and insensible losses. The significant fluid shifts in the immediate postpartum period—autotransfusion of approximately 500 mL from the contracted uterus and mobilization of third-space fluid—can transiently increase cardiac preload. Cardiac output, which peaks immediately postpartum due to relief of aortocaval compression and autotransfusion, returns to normal within two to four weeks. Heart rate, elevated during pregnancy, gradually decreases. Blood pressure typically normalizes, though close monitoring is required in women with hypertensive disorders.

Hematologic changes persist into the puerperium. A physiologic leukocytosis, with white blood cell counts reaching 15,000-30,000/μL, is normal in the immediate postpartum period and cannot reliably indicate infection. Hemoglobin and hematocrit may initially decrease due to blood loss at delivery, then stabilize or rise as plasma volume contracts. The hypercoagulable state of pregnancy persists, with clotting factors remaining elevated for weeks postpartum. The risk of venous thromboembolism is at its peak during the first six weeks postpartum, particularly the first two weeks, making VTE a leading cause of maternal mortality.

Urinary tract changes require attention. The bladder may have decreased sensation and contractility following delivery, particularly with epidural anesthesia, operative delivery, or prolonged second stage. Urinary retention is common in the immediate postpartum period and may predispose to urinary tract infection. A diuresis of accumulated pregnancy fluid occurs during the first days, with urine output sometimes exceeding 3 liters daily. The dilated ureters and renal pelves of pregnancy return to normal over weeks.

Weight loss occurs in stages. The immediate loss at delivery (fetus, placenta, amniotic fluid, blood loss) averages 5-6 kg. Additional weight loss over the first two weeks reflects diuresis and lochia. Return to pre-pregnancy weight is variable and may take six months or longer; breastfeeding promotes weight loss by increasing energy expenditure.

<image>Panel A: Cardiovascular recovery showing blood volume declining from pregnancy level to baseline over 6 weeks, cardiac output curve with immediate postpartum peak from autotransfusion (500 mL from contracted uterus) then gradual decline over 2-4 weeks. Panel B: Hematologic changes showing normal postpartum leukocytosis (15,000-30,000/uL), coagulation factors remaining elevated for weeks, and VTE risk timeline peaking in the first 2 weeks postpartum. Panel C: Urinary tract changes showing bladder with decreased sensation and contractility, dilated collecting system resolving over weeks, and diuresis of accumulated pregnancy fluid (up to 3 liters daily). Panel D: Weight loss stages showing immediate delivery loss (5-6 kg), additional fluid loss over 2 weeks through diuresis and lochia, and variable timeline for return to pre-pregnancy weight over months.</image>

Section 3: Lactation Physiology

Lactation, the production and secretion of milk, is a complex neuroendocrine process essential for neonatal nutrition. The breast has been prepared during pregnancy by hormonal influences that stimulate alveolar and ductal development, but active milk production is inhibited until after delivery.

The hormonal control of lactation centers on prolactin and oxytocin. During pregnancy, elevated estrogen and progesterone promote mammary development while simultaneously suppressing prolactin's lactogenic effects. The abrupt fall in estrogen and progesterone following placental delivery removes this inhibition, allowing prolactin to stimulate milk synthesis by alveolar epithelial cells. Suckling provides the critical stimulus for sustained lactation: sensory signals from the nipple travel to the hypothalamus, suppressing dopamine (which normally inhibits prolactin release) and triggering prolactin secretion from the anterior pituitary. This ensures milk production matches infant demand—frequent suckling increases prolactin and milk supply.

Oxytocin mediates milk ejection (the "let-down" reflex). Released from the posterior pituitary in response to suckling or conditioned stimuli (hearing the infant cry, thinking about nursing), oxytocin causes contraction of myoepithelial cells surrounding the alveoli, propelling milk into the ducts and toward the nipple. Stress, pain, and anxiety can inhibit oxytocin release and impair let-down.

Milk composition evolves through three stages. Colostrum, present from birth through days 2-4, is a thick, yellowish fluid rich in immunoglobulins (particularly secretory IgA), lactoferrin, leukocytes, and growth factors. Though low in volume (approximately 2-10 mL per feeding), colostrum provides critical immune protection and helps establish intestinal flora. Transitional milk, from days 4-14, increases in volume, fat, and lactose content as mature milk synthesis accelerates. Mature milk, established by approximately two weeks, provides complete nutrition for the infant: lactose as the primary carbohydrate, human milk fat with essential fatty acids, whey and casein proteins, and minerals and vitamins. The fat content of mature milk increases during each feeding, with hindmilk (later milk) containing more fat than foremilk.

<image>Panel A: Hormonal control of lactation showing pregnancy state (placental estrogen/progesterone inhibiting prolactin action) versus postpartum state (hormone withdrawal permitting lactation onset). Panel B: Neuroendocrine reflex arc with suckling stimulus traveling to hypothalamus, suppressing dopamine to stimulate prolactin release from anterior pituitary for milk production, and stimulating oxytocin release from posterior pituitary for let-down reflex. Panel C: Breast anatomy with alveoli, myoepithelial cells, and ductal system, with inset showing oxytocin contracting myoepithelial cells to propel milk into ducts and toward the nipple. Panel D: Milk stages with composition showing colostrum (yellow, thick, rich in IgA, lactoferrin, leukocytes), transitional milk (increasing volume and fat), and mature milk (complete nutrition with fat content variation from foremilk to hindmilk).</image>

Section 4: Breastfeeding Benefits and Common Problems

The benefits of breastfeeding are extensive for both infant and mother, and breastfeeding is recommended as the exclusive source of nutrition for the first six months of life.

Infant benefits include optimal nutrition precisely tailored to infant needs, with changing composition that adapts to growth requirements. Immunologic protection through secretory IgA coats mucosal surfaces and prevents pathogen adherence, while lactoferrin has antibacterial and antiviral properties, and leukocytes provide cellular immunity. Breastfed infants experience reduced incidence and severity of gastrointestinal infections, respiratory infections, and otitis media. Long-term benefits include reduced risk of childhood obesity, type 1 and type 2 diabetes, allergic diseases, and possibly improved cognitive development.

Maternal benefits include enhanced uterine involution from oxytocin-induced contractions during nursing, reducing postpartum hemorrhage risk. Lactational amenorrhea provides contraceptive benefit under specific conditions. Long-term benefits include reduced risk of breast cancer, ovarian cancer, type 2 diabetes, and possibly postpartum depression. The bonding facilitated by breastfeeding supports maternal-infant attachment.

Common breastfeeding problems require recognition and management. Engorgement, characterized by painful breast fullness and firmness, typically occurs around days 3-5 as milk comes in. Management includes frequent nursing, warm compresses before feeding to facilitate let-down, cold compresses between feedings for comfort, and expressing milk if the infant cannot latch on an overly full breast.

Mastitis, infection of breast parenchyma, presents with unilateral breast pain, warmth, erythema, and systemic symptoms (fever, malaise). It typically occurs 2-3 weeks postpartum and is usually caused by Staphylococcus aureus entering through a cracked nipple. Treatment includes continued breastfeeding (which helps drain the affected breast), antibiotics effective against S. aureus (dicloxacillin, cephalexin), and symptomatic measures. An undrained abscess may develop despite antibiotics, requiring incision and drainage or needle aspiration.

Cracked or sore nipples often result from improper latch and positioning. The infant should take the entire nipple and much of the areola into the mouth. Lanolin application after feeding and air drying help healing. Nipple shields may provide temporary relief but should be used cautiously as they may reduce milk transfer.

<image>Panel A: Infant breastfeeding benefits including immune protection with secretory IgA coating the gut, reduced infection rates for GI, respiratory, and otitis media, and long-term health outcomes (reduced obesity, diabetes, allergic disease). Panel B: Maternal breastfeeding benefits including enhanced uterine involution from oxytocin, reduced breast and ovarian cancer risk, decreased type 2 diabetes risk, and maternal-infant bonding. Panel C: Engorgement (bilateral firm, swollen breasts around days 3-5) with management steps (frequent nursing, warm compresses before feeding, cold compresses between feedings), and mastitis (unilateral erythematous breast with wedge-shaped inflammation, fever, S. aureus, antibiotic treatment). Panel D: Cracked nipples with close-up of damaged nipple, proper versus improper latch illustrations showing correct amount of areola in infant's mouth, and management (lanolin application, air drying, nipple shields with caution).</image>

Section 5: Postpartum Hemorrhage - Definition, Causes, and Risk Factors

Postpartum hemorrhage (PPH) is a leading cause of maternal morbidity and mortality worldwide. The traditional definition is blood loss exceeding 500 mL after vaginal delivery or 1000 mL after cesarean delivery, though revised definitions increasingly use 1000 mL or blood loss resulting in hemodynamic instability as the threshold. The quantitative measurement of blood loss, through direct collection and weighing of materials, has improved recognition.

The four T's provide a framework for PPH causes. Tone, referring to uterine atony (failure of the uterus to contract effectively), accounts for approximately 70% of PPH. When the uterus does not contract, the "living ligatures" cannot compress blood vessels at the placental site, leading to hemorrhage. Risk factors for atony include uterine overdistension (multiple gestation, polyhydramnios, macrosomia), prolonged labor, rapid labor, high parity, chorioamnionitis, magnesium sulfate therapy, and previous PPH.

Trauma accounts for approximately 20% of cases and includes lacerations of the cervix, vagina, or perineum; uterine rupture; and uterine inversion. Risk factors include operative vaginal delivery, rapid delivery, episiotomy, and macrosomia.

Tissue, referring to retained products of conception (placental fragments or membranes), causes approximately 9% of PPH. The placenta should be inspected after delivery to ensure completeness. Placenta accreta spectrum disorders, where the placenta abnormally adheres to or invades the myometrium, present particular risk.

Thrombin, encompassing coagulation disorders, accounts for approximately 1% of PPH. Pre-existing disorders (von Willebrand disease, hemophilia carriers, thrombocytopenia) may present at delivery. Acquired coagulopathy may result from massive transfusion, amniotic fluid embolism, placental abruption with disseminated intravascular coagulation, or HELLP syndrome.

Primary PPH occurs within 24 hours of delivery, while secondary (delayed) PPH occurs from 24 hours to 12 weeks postpartum, most commonly due to retained products, endometritis, or subinvolution of the placental site.

<image>Panel A: Central pie chart showing the 4 T's distribution of PPH causes: Tone (70%), Trauma (20%), Tissue (9%), and Thrombin (1%), with primary (less than 24 hours) versus secondary (24 hours to 12 weeks) PPH timeline. Panel B: Uterine atony (Tone) showing flaccid uterus with open blood vessels lacking living ligatures, with risk factors including overdistension, prolonged labor, chorioamnionitis, magnesium use, and multiparity. Panel C: Trauma showing cervical/vaginal laceration diagrams, uterine inversion, and uterine rupture, plus retained products (Tissue) with placental fragment on ultrasound and incomplete placenta on inspection. Panel D: Coagulopathy (Thrombin) showing coagulation cascade disruption, DIC with schistocytes on peripheral smear, and causes including massive transfusion, amniotic fluid embolism, placental abruption, and HELLP syndrome.</image>

Section 6: Postpartum Hemorrhage - Management

Management of PPH follows a systematic, escalating approach while simultaneously addressing resuscitation. Early recognition, quantification of blood loss, and aggressive intervention are key.

Initial assessment includes fundal massage and assessment of uterine tone. A soft, "boggy" uterus indicates atony. Bimanual uterine compression, with one hand on the fundus through the abdomen and the other inside the vagina compressing the lower segment, can provide temporary hemostasis while other measures are initiated.

Uterotonic agents are first-line pharmacologic treatment. Oxytocin (10-40 units in IV infusion) is the first agent used, stimulating myometrial contraction. Methylergonovine (Methergine, 0.2 mg IM) causes sustained uterine contraction but is contraindicated in hypertension due to vasoconstrictive effects. Carboprost (Hemabate, 15-methyl-PGF2α, 250 μg IM) is a potent prostaglandin but is contraindicated in asthma due to bronchospasm risk. Misoprostol (800-1000 μg rectally) is a PGE1 analog with no contraindications and is particularly useful in low-resource settings.

Tranexamic acid, an antifibrinolytic agent, reduces PPH-related mortality when given within 3 hours of delivery. The WOMAN trial demonstrated a significant reduction in death from hemorrhage with tranexamic acid 1 g IV.

Examination under adequate anesthesia allows assessment for lacerations requiring repair and retained products requiring removal.

If medical management fails, procedural and surgical interventions escalate. Uterine tamponade with a balloon (Bakri balloon or Foley catheter) provides compression of the uterine cavity and can be both diagnostic (if hemorrhage stops) and therapeutic. Surgical options include uterine compression sutures (B-Lynch suture), uterine artery ligation, and internal iliac artery ligation to reduce pulsatile flow. Uterine artery embolization by interventional radiology is an option if the patient is stable enough for transfer. Hysterectomy is the definitive treatment when other measures fail and is life-saving.

Resuscitation occurs concurrently and includes large-bore IV access, crystalloid infusion, and early blood product transfusion. Massive transfusion protocols provide balanced ratios of red blood cells, fresh frozen plasma, and platelets. Point-of-care testing (thromboelastography, rotational thromboelastometry) can guide component therapy.

<image>Panel A: PPH recognition (quantitative blood loss greater than 1000 mL or hemodynamic instability) with simultaneous resuscitation path (IV access, fluids, blood products, massive transfusion protocol) and source control path (4 T's evaluation). Panel B: Uterotonic ladder showing oxytocin (first-line, no contraindications), methylergonovine (contraindicated in hypertension), carboprost (contraindicated in asthma), and misoprostol (no contraindications), plus tranexamic acid 1g IV within 3 hours. Panel C: Procedural interventions including bimanual uterine compression technique, Bakri balloon insertion for uterine tamponade, and examination under anesthesia for lacerations requiring repair. Panel D: Surgical options including B-Lynch compression suture pattern on uterus, uterine artery ligation, internal iliac artery ligation, uterine artery embolization by interventional radiology, and hysterectomy as definitive life-saving treatment.</image>

Section 7: Postpartum Infections

Puerperal infection, historically a major cause of maternal mortality, remains an important postpartum complication. The genital tract is most commonly affected, though breast, urinary tract, and wound infections also occur.

Endometritis, infection of the uterine decidua and myometrium, is the most common cause of puerperal fever. The infection is typically polymicrobial, involving vaginal flora that ascend into the uterus. Risk factors include cesarean delivery (the strongest risk factor, with rates 5-10 times higher than vaginal delivery), prolonged rupture of membranes, prolonged labor, multiple vaginal examinations, internal fetal monitoring, and operative vaginal delivery. Cesarean delivery after labor or rupture of membranes carries higher risk than scheduled cesarean.

Clinical presentation includes fever (usually within 24-48 hours of delivery, though may be later), uterine tenderness, foul-smelling lochia, and malaise. The diagnosis is clinical; cultures are generally not helpful due to polymicrobial nature.

Treatment requires broad-spectrum antibiotics covering gram-positive, gram-negative, and anaerobic organisms. The combination of clindamycin (900 mg IV every 8 hours) and gentamicin (5 mg/kg IV daily) is standard, with ampicillin added if no improvement occurs (to cover enterococcus). Treatment continues until the patient has been afebrile for 24-48 hours; oral antibiotics are not routinely needed thereafter. If fever persists despite appropriate antibiotics, septic pelvic thrombophlebitis, pelvic abscess, or wound infection should be considered.

Wound infections may complicate cesarean incisions or perineal repairs. Presentation includes erythema, warmth, drainage, and wound breakdown. Management includes opening the wound to allow drainage, antibiotics, and wound care; deep infections may require debridement.

Mastitis, discussed earlier, is treated with antistaphylococcal antibiotics and continued breastfeeding. Untreated mastitis may progress to abscess requiring drainage.

Urinary tract infections, facilitated by catheterization during labor and reduced bladder sensation postpartum, present with dysuria, frequency, and fever. Treatment is with appropriate antibiotics based on culture.

<image>Panel A: Endometritis showing risk factors with cesarean delivery emphasized as highest risk (5-10 times higher than vaginal delivery), clinical presentation (fever within 24-48 hours, uterine tenderness, foul lochia), and treatment with clindamycin plus gentamicin. Panel B: Endometritis management algorithm showing addition of ampicillin if no improvement, and evaluation for septic pelvic thrombophlebitis, pelvic abscess, or wound infection if fever persists. Panel C: Wound infections showing cesarean incision with erythema and drainage, perineal laceration breakdown, and management with opening the wound, antibiotics, and wound care. Panel D: Mastitis showing breast with wedge-shaped erythema treated with antistaphylococcal antibiotics and continued breastfeeding (abscess requires drainage), and UTI showing catheterization as risk factor with culture-guided treatment.</image>

Section 8: Venous Thromboembolism Postpartum

Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism, is a leading cause of maternal mortality in developed countries. The risk is substantially elevated during pregnancy (4-5 times baseline) but reaches its peak during the postpartum period, particularly the first six weeks and especially the first two weeks after delivery.

The hypercoagulable state of pregnancy, an evolutionary adaptation to prevent hemorrhage at delivery, creates this risk. Clotting factors (I, VII, VIII, X, von Willebrand factor) are elevated. Natural anticoagulants (protein S) are decreased. Fibrinolysis is impaired. Venous stasis from the gravid uterus and immobility compounds the problem.

Additional risk factors for postpartum VTE include cesarean delivery (particularly emergency cesarean), preeclampsia, hemorrhage requiring transfusion, infection, prolonged immobility, obesity, advanced maternal age, prior VTE, and inherited thrombophilias.

Diagnosis presents challenges because symptoms overlap with normal postpartum findings. Lower extremity swelling may be attributed to dependent edema; dyspnea may be dismissed as deconditioning. A high index of suspicion is essential. D-dimer testing is not useful, as levels are elevated in normal pregnancy and postpartum. Compression ultrasonography is the initial test for suspected DVT. CT pulmonary angiography is preferred for suspected PE; ventilation-perfusion scanning is an alternative if contrast is contraindicated.

Prophylaxis is stratified by risk. Low-risk women (vaginal delivery, no additional risk factors) require only early ambulation. Moderate-risk women (cesarean delivery or multiple minor risk factors) benefit from mechanical prophylaxis with sequential compression devices. High-risk women (prior VTE, known thrombophilia, multiple risk factors) require pharmacologic prophylaxis with low-molecular-weight heparin or unfractionated heparin.

Treatment of established VTE uses anticoagulation. LMWH is preferred in the immediate postpartum period due to ease of use and predictable pharmacokinetics. Warfarin may be initiated for longer-term anticoagulation and is safe during breastfeeding. Direct oral anticoagulants have limited data in breastfeeding, and caution is advised.

<image>Panel A: Virchow's triad applied to postpartum showing hypercoagulability (elevated clotting factors), stasis (immobility, dilated veins), and endothelial injury (delivery trauma), with VTE risk timeline peaking in first 2 weeks and declining over 6 weeks. Panel B: Risk factor stratification table showing low-risk (vaginal delivery, early ambulation), moderate-risk (cesarean, sequential compression devices), and high-risk (prior VTE, thrombophilia, pharmacologic prophylaxis with LMWH or heparin). Panel C: Diagnostic algorithm showing clinical suspicion leading to compression ultrasound for DVT or CT pulmonary angiography/VQ scan for PE, with D-dimer noted as not useful in pregnancy and postpartum. Panel D: Treatment with LMWH injection technique (preferred in immediate postpartum), warfarin (safe in breastfeeding), and direct oral anticoagulants (limited data in breastfeeding, caution advised).</image>

Section 9: Postpartum Mood Disorders

Postpartum mood disorders exist on a spectrum from the nearly universal "baby blues" to the psychiatric emergency of postpartum psychosis. Recognition and appropriate management are essential, as these conditions significantly affect maternal and infant well-being.

Postpartum blues ("baby blues") affects 50-80% of women and represents a normal response to the dramatic hormonal shifts, sleep deprivation, and life adjustment following delivery. Symptoms include mood lability, tearfulness, irritability, anxiety, and difficulty sleeping, appearing within the first few days and resolving by two weeks. No treatment beyond reassurance and support is required. However, if symptoms persist beyond two weeks or are severe, evaluation for postpartum depression is indicated.

Postpartum depression affects 10-15% of women and represents a major depressive episode with onset in the perinatal period. Symptoms include depressed mood, anhedonia (loss of pleasure in activities), sleep disturbance beyond that caused by infant care, fatigue, appetite changes, feelings of worthlessness or guilt, difficulty concentrating, and thoughts of death or suicide. Risk factors include prior depression or anxiety, history of postpartum depression, psychosocial stressors, lack of social support, and unintended pregnancy.

Screening is recommended at postpartum visits using validated instruments such as the Edinburgh Postnatal Depression Scale (EPDS). A score of 10 or higher suggests depression and warrants further evaluation. Treatment includes psychotherapy (particularly cognitive-behavioral therapy and interpersonal therapy) and pharmacotherapy with selective serotonin reuptake inhibitors; sertraline is often chosen due to low transfer into breast milk.

Postpartum psychosis is a psychiatric emergency occurring in 0.1-0.2% of deliveries. Onset is typically rapid, within the first two weeks postpartum, often within days. Symptoms include confusion, disorientation, delusions (often involving the infant), hallucinations, severe mood instability, and agitation. The strongest risk factor is bipolar disorder; women with bipolar disorder have a 25-50% risk of postpartum psychosis. The risk of infanticide and suicide is significant. Treatment requires hospitalization, antipsychotic medication, mood stabilizers, and close supervision. Mother-infant separation may be necessary for safety.

<image>Panel A: Mood disorder spectrum bar showing baby blues (50-80%), postpartum depression (10-15%), and postpartum psychosis (0.1-0.2%), with typical onset timeline for each disorder. Panel B: Baby blues with mild symptoms (tearfulness, mood swings, irritability), timeline (days 3-10, resolving by 2 weeks), and reassurance as management, noting evaluation for depression if symptoms persist beyond 2 weeks. Panel C: Postpartum depression with EPDS screening questionnaire (score 10 or higher suggests depression), symptoms (depressed mood, anhedonia, guilt, suicidal ideation), risk factors (prior depression, stress, lack of support), and treatment (CBT, interpersonal therapy, sertraline). Panel D: Postpartum psychosis as psychiatric emergency with rapid onset within first 2 weeks, symptoms (confusion, delusions about infant, hallucinations, agitation), bipolar disorder as strongest risk factor (25-50% risk), infanticide and suicide danger, and treatment requiring hospitalization with antipsychotics and mood stabilizers.</image>

Section 10: Postpartum Care and Contraception

Postpartum care encompasses hospital management, outpatient follow-up, and anticipatory guidance for the family's transition.

Hospital care includes monitoring for hemorrhage (vital signs, fundal checks, bleeding assessment), pain management (multimodal approach with NSAIDs, acetaminophen, and opioids as needed for severe pain), support for breastfeeding (lactation consultant availability), Rh prophylaxis with RhoGAM if the mother is Rh-negative and the infant is Rh-positive, and education about warning signs (heavy bleeding, fever, severe headache, leg swelling, chest pain, thoughts of harming self or infant).

The postpartum visit, traditionally at six weeks, is increasingly recognized as insufficient. The American College of Obstetricians and Gynecologists recommends ongoing postpartum care as a process rather than a single encounter, with contact within the first three weeks and a comprehensive visit by 12 weeks. The comprehensive visit includes assessment of physical recovery, mood screening, management of chronic conditions (blood pressure follow-up after hypertensive disorders, glucose testing after gestational diabetes), breastfeeding support, and contraception counseling and provision.

Return of fertility is variable. In non-breastfeeding women, ovulation may return as early as four weeks postpartum. Breastfeeding delays ovulation, but the timing is unpredictable. The lactational amenorrhea method (LAM) provides effective contraception (>98% efficacy) only when three conditions are met: exclusive breastfeeding, amenorrhea, and infant less than six months old.

Contraceptive options in the postpartum period require consideration of timing and breastfeeding. Long-acting reversible contraception (IUDs and implant) can be placed immediately postpartum or at the postpartum visit and is highly effective regardless of breastfeeding. Progestin-only methods (progestin-only pills, DMPA, implant, hormonal IUD) are safe immediately postpartum and during breastfeeding. Combined hormonal contraceptives (pills, patch, ring) should be delayed until 21-42 days postpartum due to VTE risk and until 4-6 weeks if breastfeeding due to potential effects on milk supply. Sterilization can be performed postpartum (tubal ligation or salpingectomy at cesarean or via minilaparotomy) or at interval.

<image>Panel A: Hospital care components including vital signs monitoring, fundal assessment technique, multimodal pain management, breastfeeding support with lactation consultant, and RhoGAM administration for Rh-negative mother with Rh-positive infant. Panel B: Warning signs checklist (heavy bleeding, fever, severe headache, leg swelling, chest pain, thoughts of harming self or infant) and outpatient care timeline with early contact within 3 weeks and comprehensive visit by 12 weeks. Panel C: Comprehensive visit components including mood screening with EPDS, blood pressure follow-up for hypertensive disorders, glucose tolerance testing after GDM, breastfeeding support, and contraception counseling. Panel D: Contraceptive timing showing immediate options (IUD, implant, sterilization), progestin-only (any time, safe with breastfeeding), combined hormonal (after 21-42 days, after 4-6 weeks if breastfeeding), and LAM criteria (exclusive breastfeeding plus amenorrhea plus infant less than 6 months).</image>

Summary

The puerperium (6 weeks postpartum) involves uterine involution (fundus descends from umbilicus to non-palpable by 6 weeks), lochia progression (rubra to serosa to alba), and return of physiologic systems to baseline.

Lactation is controlled by prolactin (milk production) and oxytocin (let-down). Milk stages progress from colostrum (immunoglobulins) to transitional to mature milk. Breastfeeding benefits include optimal infant nutrition, immune protection, reduced maternal cancer risk, and bonding.

Postpartum hemorrhage is most commonly caused by uterine atony (70%). The 4 T's framework (Tone, Trauma, Tissue, Thrombin) guides evaluation. Management includes fundal massage, uterotonics (oxytocin, methylergonovine, carboprost, misoprostol), tranexamic acid, balloon tamponade, surgical intervention, and resuscitation.

Endometritis is the most common puerperal infection, with cesarean delivery as the strongest risk factor. Treatment is clindamycin plus gentamicin.

VTE risk is highest in the first 2 weeks postpartum. Prophylaxis is stratified by risk. Treatment uses LMWH or warfarin (safe in breastfeeding).

Postpartum mood disorders range from baby blues (50-80%, self-limited) to depression (10-15%, screen with EPDS, treat with SSRIs) to psychosis (0.1-0.2%, psychiatric emergency requiring hospitalization).

Contraception: LARC can be placed immediately; progestin-only methods are safe with breastfeeding; combined hormonal methods should be delayed 21-42 days (longer if breastfeeding).

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown